Furthermore, the specific binding of CD24-targeting fluorescence contrast agents to CD24+ tumor cells has been reported in preclinical metastatic cell lines and PDX models, which support its use as a theranostic biomarker [14,19]. This evidence concerns the gene CD24 and neoplasm.